I The measurement of serum follicle stimulating hormone (FSH) and luteinising hormone (LH), together with the appropriate sex steroid, is of great value in the investigation of delayed and precocious puberty, hypogonadism, subfertility, polycystic ovarian disease and hypothalamic-pituitary disorders. Dynamic function testing of the hypothalamic-pituitary-gonadal axis should be restricted to a few defined situations. Sequential LH measurements, either in serum or in urine, may be used to time ovulation during artificial insemination or in vitro fertilisation programmes.
SUMMARY
I The measurement of serum follicle stimulating hormone (FSH) and luteinising hormone (LH), together with the appropriate sex steroid, is of great value in the investigation of delayed and precocious puberty, hypogonadism, subfertility, polycystic ovarian disease and hypothalamic-pituitary disorders. Dynamic function testing of the hypothalamic-pituitary-gonadal axis should be restricted to a few defined situations. Sequential LH measurements, either in serum or in urine, may be used to time ovulation during artificial insemination or in vitro fertilisation programmes.
2 No special precautions are necessary when sampling for FSH and LH measurement; serum is preferred to plasma and should be stored frozen before assay. Aliquots of timed urine specimens of known volume should be stored frozen without preservative. 3 Gonadotrophin results should be available within 2-3 weeks: laboratories unable to meet this schedule are advised to send their samples to a Regional Centre for assay. 4 Reagents for the radioimmunoassay of FSH and LH are readily available, and standard techniques have been developed for their use. Laboratories using 'inhouse' methods should pay particular attention to the matrix used for preparing standard solutions, the purification of radioligands and the optimisation of the separation system. Low cost matched reagents of proven performance are available in kit form from the Chelsea Hospital for Women: several commercial kits are also available, although few are widely used in the UK. 5 The overall performance of laboratories in the UK External Quality Assessment Scheme (EQAS) for FSH and LH has remained steady for several years. Of the 130 participants, only about 15% in each scheme have 'good' performance (cumulative bias less than 10%, plus cumulative variability of bias less than IO'Yu), whilst a similar proportion have 'unacceptable' performance (cumulative bias greater than 20% and/or cumulative variability of bias greater than 25%). The remaining 70% of laboratories have 'adequate' performance but are at risk of producing results This paper was prepared at the invitation of the Analytical Methods Working Party of the SCientificCommittee of the Association of Clinical Biochemists. but docs not necessarily reflect the views of the Scientific Committee.
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that are clinically misleading. Within anyone method group, the performance of FSH and LH assays are closely related. 6 Optimal assay performance depends upon sensible laboratory management to ensure skilled operators, a regular programme of reagent/kit renewal, comprehensive internal and external quality assessment, and attention to detail in all aspects of gonadotrophin assay. The working range of each individual assay should be defined and no absolute result reported from outside this range. Mean intra-assay and interassay coefficients of variation on selected human serum quality control pools should be better than 8% and 15%, respectively, for both gonadotrophins. All laboratories performing FSH and LH assays should belong to the UK EQAS for gonadotrophins. 7 Immunometric assays, using monoclonal antibodies, will supersede radioirnmunoassays for FSH and LH during the next few years. Some of these assays will have non-isotopic labels. This paper summarises guidelines for the provision of a clinical biochemistry service for follicle stimulating hormone (FSH) and luteinising hormone (LH). Five objectives were identified: I To review the clinical applications of assays for FSH and LH. 2 To define the characteristics of assays suitable for meeting this need. 3 To review critically the available methods for FSH and LH. 4 To comment on the relative performance of available methods. 5 To make recommendations which should lead to an overall improvement in the performance of these assays. The paper will address each of the first four objectives in sequence. Recommendations for improved performance appear throughout the text, but the main recommendations have been restated as the summary to the paper.
I Clinical applications of assays for FSH and

LH
The gonadotroph cells of the anterior pituitary are unusual in that they synthesise and secrete two distinct peptide hormones, FSH and LH. 1 The hormones are dimers with a common a-chain and unique l3-chains; they have a molecular weight of approximately 28 000, of which 20% is estimated to be carbohydrate side-chains. FSH and, to a greater extent, LH are secreted in a pulsatile manner in response to the hypothalamic decapeptide gonadotrophin releasing hormone (GnRH).2 The factors involved in the control of FSH and LH secretion are complex and incompletely understood.I In males, FSH stimulates spermatogenesis; in females, it stimulates the growth of follicles and, in conjunction with LH, oestrogen secre-tion and ovulation. LH in males stimulates androgen secretion by the Leydig or interstitial cells of the testis, and in females it promotes the formation of corpora lutea and progesterone secretion.
Only the clinical situations in which gonadotrophin measurements are well established will be highlighted in this report, which does not attempt to review the physiology and pathology of gonadotrophin secretion. Many dynamic tests of the hypothalamic-pituitary-gonadal axis (HPGA) have been described, the most widely used being the gonadotrophin releasing hormone test (GnRH Test) and the clomiphene stimulation test. Practical details of the performance of these tests and a guide to their interpretation have been published."
Patients need not be fasted before taking blood for gonadotrophin levels, nor are any special precautions necessary with respect to posture, stress or physical activity at the time of sampling; in adults, there is no circadian variation in plasma levels of FSH and LH. Hypothalamic GnRH is released in short bursts that occur every 60-90 min, each of which results in a clear pulse of LH some 2-4 UIL above baseline and a rather less obvious pulse of FSH. For most clinical purposes, a single basal sample taken at any time of day will yield adequate information, although a more detailed study of pulsatility may be necessary In selected patients. Nocturnal pulses of LH can provide the first biochemical evidence of the onset of puberty, and it may be of value to look for these in certain subjects.
Reference ranges for FSH and LH are difficult to define, for they are influenced by age, sex, degree of sexual development, drug treatment and, in the female, menstrual status and pregnancy. 'ndividual laboratories should obtain their own reference data; those given in Table I should be used only as a general guide.
The remaining part of this section deals briefly with the role of gonadotrophins in the aetiology and investigation of abnormalities of gonadal function. Table 2 summarises those clinical situations in which the measurement of serum levels of FSH and LH is of recognised value.
I'AEDIATRIC AND ADOLESCENT DISOI<DERS
Delayed puberty This is a common paediatric endocrine problem, especially in boys. but its investigation is complex. involving a number of' different clinical and biochemical indices." In all cases the plasma sex steroid status of the individual should be determined at the same time <IS FSH and LH measurements are made. On the basis TABLE l. The reference ranges for FSH (U/L of 7R1549) and LH (U/L of OR/4(1) obtained by the Hospital for Women, Birmingham. Excluded from these data are changes which occur during different stages of puberty. These data should be used for guidance only, and each laboratory should establish its own reference range data of these initial investigations. delayed puberty can he categorised into two broad groups. Hypergonadotrophic hypogonadism ischaracterised by elevated levels of gonadotrophins in the presence of relatively low levels of plasma sex steroid. a combination diagnostic of primary gonadal failure. Once this diagnosis has been confirmed. repeated measurements of gonadotrophins arc not necessary and dynamic testing of the pituitary-gonadal axis has no place in the further investigation of these patients. Screening for primary gonadal failure by measuring FSB (many laboratories also measure L11) should always take place at an early stage in the study of a child with delayed puberty.
Hypogonadotrophic hypogonadism is more common and presents greater diagnostic problems. The condition is characterised by undetectable or 'low normal' levels of FSH and LH in the presence of sex steroid depletion. However. the definitive diagnosis of gonadotrophin deficiency in the pre-pubertal child is difficult for four reasons. Firstly. the relative insensitivity of existing assays for FSH and LH means that a proportion of normal subjects will have undetectable gonadotrophins as they approach puberty. Secondly, there is a dissociation between immunoassayable and biologically active FSH and LH in these children. Thirdly. there is significant physiological variability in basal FSII and LH levels which makes onepoint investigations of limited value. Finally. a proportion of subjects with hypogonadotrophic hypogonadism have an apparently normal FSH and LH response to GnRH and other dynamic function tests. '\ A detailed clinical history and follow-up is vital to the efficient investigation of hypogonadotrophic hypogonadism. Some patients have destructive lesions of the pituitary and so are almost certain to be gonadotrophin deficient und merit treatment at a relatively early stage. However, delayed puberty usually results from an isolated deficiency of hypothalamic GnRH. Whilst a minority of these patients may have signs or symptoms of hypothalamic or pituitary disease. such as anosmia (Kallman's syndrome), deft palate or other anatomical abnormalities. most children lack these features. Once the hypogonadotrophic state has been established. it is common practice to follow these individuals for several years on the assumption that they have constitutional delayed puberty. which is simply a delay in the normal maturation of the hypothalamus. In the Assays for FSH and LH 249 absence of clinical evidence. the diagnosis of true hypogonadotrophic hypogonadism can only be reached when the patient is 18-20 years of age.
In hypogonadotrophic hypogonadism, there is usually a parallel decrease in the levels of both FSH and LH. However, a small group of males with eunuchoid features have LH deficiency and low testosterone levels but FSH levels sufficient to stimulate spermatogenesis. These patients constitute the fertile eunuch syndrome.
Basal gonadotrophin measurements are important in the initial diagnosis of the hypogonadotrophic state. Thereafter, occasional basal FSH and LH determinations may be performed, but sex steroids are of more value in monitoring the progress, or lack of it, into puberty." In a few selected patients. the detailed study of nocturnal LH pulsatility may be justified. Current dynamic function tests have little or no place in the investigation of hypogonadotrophic hypogonadism.
Precocious puberty
Precocious puberty, which is a less common problem than delayed puberty, is also a heterogeneous group of disorders which can be broadly classified into two categories." True precocious puberty is always isosexual, and in these children the HPGA is activated at an unusually young age; FSH and LH levels move to within the adult reference range, as do responses of GnRH and clomiphene. Existing gonadotrophin assays are satisfactory in detecting true precocious puberty, but do not help to make a definitive diagnosis. Approximately 90% of female cases are labelled idiopathic; by contrast. over SO% of male cases are secondary to intracranial space-occupying lesions. A small group of patients with true precocious puberty have FSH and LH levels which are undetectable by existing assays."
In pseudo-precocious puberty. the HPGA is not activated. FSH and LH levels are suppressed to within pre-pubertal levels, as are the responses to dynamic tests of the HPGA. The sex steroids which stimulate the development of the pubertal features in these patients come either from tumours of gonadal or adrenal tissue or from gonads stimulated by human chorionic gonadotrophin (hCG) from a teratoma. For this latter group. it is essential that FSH and LH assays do not cross-react with hCG. For the diagnosis of pseudo-precocious puberty. hCG and steroid hormone measure-ments are more important than FSH and LH measurements.
PITUITARY DISORDERS IN ADULTS
In sexually mature adults, gonadotrophin deficiency is usually an early feature of the development of panhypopituitarism. Gonadotrophin deficiency, which usually presents clinically earlier in females than males, is easily diagnosed by demonstrating low FSH and LH levels in the presence of low levels of serum testosterone in males or oestradiol in females. This may be confirmed by demonstrating an absent or impaired response to exogenous GnRH. In obviously post-menopausal females the GnRH test is superfluous since premenopausal basal FSH and LH levels are indicative of hypogonadotrophism. Adrenal function and thyroid function should also be assessed in patients who may have panhypopituitarism. Hypopituitarism is a heterogeneous condition, and a firm diagnosis should be sought in all cases.
Primary gonadotrophin secreting tumours of the pituitary are extremely rare. Patients usually have pituitary macroadenomas and visual disturbance; the serum gonadotrophin levels are grossly elevated with high levels of a-chains. K Gonadotrophin-secreting tumours can occur secondary to gonadal failure. and the ectopic production of gonadotrophins by tumours has been reported ,II although the latter condition is extremely rare. SUBFERTILITY Gonadotrophin measurements are essential in excluding or confirming the presence of gonadal failure, which is an absolute cause of infertility. FSH levels are relatively more elevated than LH levels. Patients in the early stages of gonadal failure with serum FSH levels moderately raised may occasionally be fertile, but when levels are greater than 25 U/L gonadal failure is inevitable. The prevalence of gonadal failure is uncertain, but it accounted for 7% of cases in one unselected series of female subfertility.!" In patients with primary amenorrhoea, gonadal failure usually results from gonadal dysgenesis, and chromosomal studies should be performed in these patients.
In the female, gonadotrophin measurements may be used, with ultrasound. in the diagnosis of the polycystic ovary (peO) syndrome. The LH level is usually raised. often greater than 20 U/L, and the FSH level is normal or lownormal. An LH/FSH ratio of greater than 3: I is strong evidence in favour of the peo syndrome. These patients usually also have high levels of testosterone and androstenedione. which are thought to be important in the clinical manifestation of the syndrome. I I There is no indication for sequential gonadotrophin measurements.
Several dynamic tests of the hypothalamicpituitary-ovarian axis involve gonadotrophin measurements. However. their roles in the investigation of the subfertile female have not been definitely established. Ill. 12 In males with normal secondary sexual characteristics. nothing can be gained from measuring LH levels. However. FSH measurements are very important in the assessment of the subfertile male with a sperm concentration less than Sx IOI>/mL. High FSH levels then indicate the presence of germ cell aplasia in some or all of the seminiferous tubules. and there is it very good correlation between the FSH level and the histological grading of the testicular dysfunction. D A normal FSH level in the azoospermic male is diagnostic of obstruction of the excurrent ducts.
The role of the GnRH stimulation test or other dynamic tests has not been established in the investigation of male subfertility.
IN VITRO FERTILISATION
In in vitro fertilisation programmes. LH measurements In serum or unne are otten used to determine the timing of ovulation so that the ovum may be harvested. Programmes which do not rely upon the natural cycle usually employ ultrasound and/or urinary or serum oestrogen measurements to monitor the progress of the developing follicles. 14 
FSH ANI) I.H IN URINE
Proteins the size of the gonadotrophins are filtered at the glomerulus at J(~2I)fX, of the glomerular filtration rate and can be readily detected in urine. FSH and LH are present in urine in approximately the same concentration as in serum. Urinary gonadotrophin levels may be used to define day-to-day changes seen in the menstrual cycle <IOd the gross changes which occur in gonadal failure. Wide intra-and inter-individual fluctuations in the rate of filtration and catabolism of the glycoproteins has limited the value of urinary FSH and L11 measurements for most routine clinical purposes, other than in vitro fertilisation or artificial insemination.
2 Characteristics required of assays for FSH and LH
SPECIMEN REQUIREMENTS
Serum is preferred to plasma, and a minimum volume of 1·1) mL is required. Haemolysed, lipaemic or icteric samples should not be used. FSH and LH appear to be stable in serum for 8 days at room temperature.": Ih for 14 days at 4°C. l h and for five freeze-thaw cycles. I~Specimens may. therefore. be sent to the laboratory by first-class post at ambient temperature. but should be stored refrigerated or frozen at or below -21)°C. Urine specimens should be aliquots from timed collections and should not contain preservative. Each aliquot should be marked with the period of collection and the total urine volume of that collection. Urine specimens should be stored frozen at or below -21)°C.
ASSAY MANAGEMENT
All analyses of standards. quality controls and unknowns should be based on duplicate determinations. All laboratories in the UK performing FSH and LH assays should participate in the UK EQAS. For optimal clinical usefulness FSH and LH assays should be performed at least once a week to ensure an assay turnaround time of less than 2 weeks. Laboratories with relatively small workloads (i.e. less than 21) specimens a week) should consider sending the samples to a regional centre for analysis.
As with any other immunoassay. the quality and experience of the operator will have a major influence on the performance of assays for FSH and LH. A balance must be reached between the need for operator stability for optimal performance on the one hand and staff training and rotation on the other. Operator change-over should be phased so that the new operator has time to overlap and train on the assays before assuming responsibility for them. For use as assay calibrants, FSH and LH standards must be used in a suitable matrix. Ideally. this should be hormone-free serum, but it is virtually impossible to prepare large batches of human serum that are devoid only of FSH and LH. Consequently. aqueous bufferbased standards are employed commonly. although protein (for example ()·5% bovine serum albumin) is included to minimise nonspecific binding of analyte to the assay tube. Major 'matrix effects' may occur at the separation stage of the assay, and it is essential that each batch of second antibody and non-immune carrier serum is tested with both aqueous standards and serum samples. The effect of serum in accelerating the rate of the second antibody-first antibody reaction may be mimicked by the addition of high molecular weight materials such as polyethylene glycol or dextran. IX. 1\1
STANDARDS FOR FSH AND LH
ANTISERA FOR FSH AND LH
Most assays for serum FSH and LH currently employ the technique of radioimmunoassay (RIA). High titre. high specificity rabbit antisera suitable for RIA of FSH and LH have been available for several years from Professor W R Butt, Department of Biochemical Endocrinology, The Birmingham and Midland Hospital for Women, Birmingham. UK. These antisera (FSH M93/2: LH F87/2) are the basis of most 'in-house' assays in the UK. and similar antisera are used in 'kits' distributed by The Chelsea Hospital for Women (contact K.M.F.).
Polyclonal antisera and matched monoclonal antibodies against both FSH and LH will be available from a number of centres within the next 2-3 years for use in the new generation of two-site immunometric assays.
FSH AND lH ANTIGEN FOR I.ABEI.LlNG
A series of batches of highly purified human FSH and LH for radioactive labelling have been prepared in the Department of Biochemical Endocrinology, The Birmingham and Midland Hospital for Women. These preparations have minimal contamination with cross-reacting peptides and their subunits. Typical biological potencies are 29()() IU/mg for FSH and 12300 U/mg, for LH. as measured by RIA (S S Lynch, personal communication).
A number of methods have been developed for the iodination of FSH and LH. These include the use of chloramine T. 211. 21 lactoEeroxidase,22
iodogen.P N-bromo-succinimide 4 and conjugation labelling." No single iodination procedure has a major advantage over the others. and in all cases it is essential to purify the reaction product in order to remove unreacted radioactive iodide and any contaminants originally present in the protein or produced by the iodination procedure itself. Serious assay bias may result from the presence of significant amounts of such contaminants.j'': 21>
Following iodination. adequate purification may be achieved by the use of gel filtration chromatography using Ult roge I AcA 54 211 or Sephadex G-100Y Methods for the assessment of the quality of individual preparations of labelled antigen have been described." Once purified. a particular batch of labelled antigen may be used throughout its shelf-life of 4-5 weeks without purification. Purified FSH and LH labels of high quality are available at low cost from The Chelsea Hospital for Women (contact K.M.F.). and it is recommended that laboratories establishing 'in-house' FSH and LH assays for the first time should use this source of material rather than produce their own.
Monoclonal antibodies may be iodinated by standard procedures prior to their use in two-site immunoradiometric assays for FSH and LH. 2 '1
SEPARATION OF BOUND AND FREE FRACTIONS
A key stage of RIA involves the separation of bound and free antigen, in order to estimate the distribution of label between these fractions. Ideally, this separation should be complete or the resulting misclassification errors may pro-duce bias and/or imprecision. Furthermore. the technique should be rapid. technically simple. inexpensive and free from matrix effects.
The double antibody technique is most commonly used but. in its simplest form. the time to achieve maximum precipitation may be prolonged. and the efficiency of precipitation" and the rate at which it occurs I" differ in the presence or absence of serum. The inclusion of high molecular weight polymers. such <IS polyethylene glycol, polyvinyl pyrrolidone and dextran. IX. 1' 1.."' ..'1 will effectively mimic the effect of serum and significantly reduce the incubation time required for complete precipitation. Alternatively. the second antibody can be coupled to a solid phase support which may be centrifugedv or sedimented with a magnetic field .. '"
In two-site immunometric assays. separation is usually achieved hy linking one of the antibodies to a mechanical support of solidphase. Commonly used solid-phases are the sides of plastic reaction tubes or microtitre plates. glass or plastic beads and various dextran gel particles. Maximum sensitivity from these assays depends upon rigorous washing at the separation stage. The sucrose layering technique" provides an efficient separation system for assays using antibodies coupled to gel particles.
PERFORMANCF. REQUIREMENTS
Existing RIAs for FSH and LI I <Ire capable of achieving sensitivities of about 0·5 U/L and 1·0 U/L, respectively; this is adequate for most. but not all, clinical purposes. Two-site immunometric assays <Ire theoretically capable of achieving a sensitivity of 0·1 U/L for both analytes, and this may prove valuable in the investigation of low gonadotrophin states.
The sensitivity of an assay (the lowest concentration of the analyte which can be distinguished from zero) is a function of the slope of the dose response curve and the precision of each observation. It is best estimated from the precision profile of the. assay.": .", which can also be used to determine the upper limit of the working runge of the standard curve. The working range of an RIA should ideally be determined from the precision profile for each individual assay ,.~' but in the absence of such data. and as a rough guide, it will be between l)()'X. and 15'Yo of the specific binding (zero binding less non-specific binding). Sample results should never be extrapolated from the extreme ends of the dose-response curve.
The working range of any standard curve is influenced by many factors, including the exact nature of reagents and the age of the radioactive tracer. Assays for serum gonadotrophins are known to be susceptible to matrix effects;" which arise largely because of differences hetween the protein content of the standard tubes and those containing unknown serum samples. An incorrect matrix can yield biased results on basal samples and a lack 'of parallelism, as high gonadotrophin samples arc assayed at different dilutions. Using 1)·1)5 M phosphate buffer, pH 7·4. containing I)·S'X, bovine serum albumin, as the matrix for the standards, it should be possible to obtain unbiased results on basal samples, quantitative recovery of FSH and LH added to serum. and results from high samples which dilute in a parallel fashion (i.c. all data read from the working range of the assay should yield results. corrected for dilution, within 15'},0 of the mean).
The specificity of an assay for FSH and LH is determined largely by the antiserum employed. Using the reagents described above, FSH RIAs should he highly specific, with less than 1% cross-reactivity from LIt. TSH, hCG or from their free u or l~-chains. This is quite adequate for all clinical purposes. In contrast, most antisera against L11 show significant crossreactivity with hCG, such that Lli estimations are invalid in pregnant subjects or individuals with hCG secreting tumours. Interference from high circulating levels of TSII in untreated hypothyroid patients can also result in falsely elevated LI f levels.
INTEKNtd, QUAI.fTY ('ONTKO!.
The same general rules apply to assays for FSH and L11 as for any other hormone measured by an immunoassay technique: these are dealt with in depth elsewhere .:'x, ,\<I The purpose of internal quality control is to monitor intra-assay and inter-assay precision and to ensure that results are reported only from assays which meet previously established control criteria.
Intra-assay (within-batch) precision is best assessed in every assay by examining the dose error relationships of the duplicate determinations of all standards, quality control samples and unknown specimens. These data can be used to construct a precision profile .:" Assays for FSH and LI f should perform with intraassay precision of better than X% CV across the working range of the curve.
Imer-assay (between-hatch) precision should be assessed by including in every assay at least
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three human serum quality control pools distributed in random positions throughout the assay. These pools should cover the physiological range of values encountered in the samples being assayed. Suitable analyte concentrations for FSH are 2, 6 and 18 UlL and for LH are 4. 12 and 36 U/L; a lower concentration pool should be included if samples from patients with hypogonadotrophic states are routinely assayed. Inter-assay coefficients of variation for FSH and LH assays should always be less than 15% and should aim to be better than 10%.
The choice of material for quality control pools for FSH and LH assays is important. All material should he serum, and human in origin, and each individual donation must be shown to be free from hepatitis B antigen and HTLV III antibody. Sufficient serum is required to last for a 12-month period, and it should be stored in individual assay aliquots, either Iyophilised or frozen below -20°C. Care should be taken to ensure complete reconstitution of Iyophilised material before use. A number of suitable commercial preparations of quality control serum arc now available (Table 3) , but assigned values must he interpreted with caution. An overlap of at least 10 assays should be allowed when establishing new quality control pools. so that action limits can he set for the new material.
An essential feature of the quality control of any assay is the record that is kept of parameters from each assay batch. Gonadotrophin assays do not differ from those of other analytes in this respect. and readers are referred elsewhere for detailed discussions of quality control charts;": .w computer programs available to fit raw data.~lI,~I and criteria used for the rejection of an individual sample result or an assay hatch .: 1X
EXTERNAL QUALITY ASSESSMENT
All UK laboratories performing assays for FSH and LH should participate in the DHSS/SHHDsupported UK EQAS for these hormones. These schemes monitor the relative bias of individual laboratories and give an indirect index of assay precision by monitoring the variability of that bias. Laboratories should aim to achieve a cumulative mean bias within ± 10% and a cumulative variability of less than 10%, which are realistic levels of performance achieved by a significant proportion of laboratories. The EQAS Steering Committee for thyroid and peptide hormones has recom- mended that cumulative hias of greater than ± 20'X. and cumulative variability of bias of greater than 25% should he considered as unacceptable.
Methods available "or the assay of FSH and LH
Almost 65% of the laboratories performing
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FSH and LH assays in the UK use RIA methods with a common core of reagents. Almost all 'in-house' methods and both the 'Chelsea (liquid phase) kif and the 'Chelsea (solid phase) kif (Chelsea Hospital for Women. London. UK) use standards from NIBSC (FSH 78/549: LH 68/40). antiserum raised in Birmingham (e.g. FSH M93/2: LH F87/2). and highly purified preparations of FSH There are approximately 20 commercial assay systems for FSH and LH. Most are RIAs, although a variety of approaches are used to speed up the separation stage of the assay. Of these kits, only the Amerlex FSH and L11 kits (Amersham Internation...1 pic, Aylesbury, Bucks, UK) and the SimulTRAC kit (Becton Dickinson UK Ltd, Oxford, UK) are used by more than three participants in the UK EQAS. Information on protocols and characteristics of these methods is available in tabulated form upon request (contact G . H. B. ) .
A small number of methods use new technology (see Section 5) . These are worthy of a brief description, for they have the potential to offer greater convenience and/or improved performance characteristics when compared to classical RIA (Fig. I) . The potential of these new methods has yet to he proved in routine practice.
The SimulTRAC FSHlLH kit allows for the simultaneous determination of FSII and LH in a single assay tube. The kit employs specific antisera, a conventional I~'I-FSH tracer, a "Co-LH radioactive tracer and the basic RIA principle. Following the separation stage, the content of each radioisotope is determined in the bound fraction by either dual isotope counting or by repeat counting.
Three immunoradiometric assays (IRMAs) are now available for each gonadotrophin. The Sucrosep'['" FSH and LH assays (Boots-Cellteeh Diagnostics Ltd, Slough, UK) use 12'1-labelled monoclonal antibodies, sheep polyclonal antisera coupled to Sephacryl and density sedimentation separation.' 14 The NETRIA FSH and LH IRMAs (NETRIA, St Bartholomew's Hospital. London, UK) also employ appropriate mI-monoclom\1 antibodies and solid phase-linked polyclonal antisera. In contrast, the Gamma-B FSH and LH IRMAs (RIA (UK) Ltd, Washington, Tyne and Wear, UK) use an affinity purified polyclonal antiserum as the labelled species. All three of these IRMA systems offer same-day assays with improved sensitivity and wider working ranges than RIA.
By the end of 19X5, there was only one commercially available non-isotopic igonado-trophin assay kit. The Delfia IM LH kit (LKB Instruments Ltd, South Croydon. UK) is a two-site immunofluorometric assav based on two different monoclonal antibo(iies. one of which is coupled to the walls of a microtitre plate, whilst the other is labelled with an europium chelate. After the separation stage, the europium in the hound fraction is assessed by time-resolved fluorescence. 4~This assav has the advantages of the IRMAs. coupled with a much increased signal.
CIIOICE OF METlIO!)
A laboratory setting up FSI I and LH assays for the first time must consider a number of points before selecting a particular method. Aside from the obvious factors such as cost. availability and compatibility, the potential user should look for proven performance especially in the UK EQAS. There is no compelling reason for a laboratory to set up new 'in-house' RIA methods for FSI/ and UI. as methods of proven performance are available at minimal cost from the Chelsea Hospital for Women. None of the commercial kits for FSH and LH has yet been shown to offer improved performance over the Chelsea (liquid phase) methods (sec Section 4). However, newer methods are likely 10 make an impact (see Section 5) , and the potential user should update this assessment hy contact with the organisers of the UK EQAS before finally selecting a method. Any method that is new to a laboratory should be evaluated according to a recognised protocol.v' 4 Relative performance of available methods for FSH and LH The 'in-house' evaluation of a method and the routine internal quality control of that method are important in assessing its day-to-day performance, but external quality assessment is unique in providing data on comparative performance in a wide range of laboratories under routine conditions, In the UK, participation in the UK EQAS for FSI I and LH is available free of charge to all laboratories providing a clinical service, The Schemes are organised by Dr J Seth and Mr I Hanning, Immunoassay Section, Department of Clinical Chemistry, 12 Bristo Place, Edinburgh EHI lED, UK. Five coded serum pools are distributed each month for both analytes to participating laboratories. The consensus value, calculated as the alllaboratory trimmed mean (ALTM) is taken as the correct value for each pool. It is not possible to prove that the AL TM is accurate. hut addition of analytc as IRP 6X/40 or preparation 7X/541.J to pools gave mean recoveries estimated from the ALTM of 105% for FSH and 112% for L11. The performance of each participating laboratory is expressed ilS the mean bias for each result over a 6-month period from the AL TM (cumulative mean bias) and the geometric CV of that hias (vuriability of the bias), At the time of writing (April 11.Jl{6). there arc 130 participants in the UK EQAS and these are using a relatively limited number of methods. as descnhcd in Table 4 . Because of the small numbers of participants using some methods. information about relative method performance is available for only six methods.
Amerlex and Amerlex-M have been pooled. Agreement between Amerlex users appears to be best, except at low concentrations of LH. There is no marked difference between the 'in-house' and Chelsea method groups, although users of the liquid-phase Chelsea method appear to have slightly better betweenlaboratory precision than users of the solid phase version. Figures 4 and 5 show the cumulative mean bias and variability of bias for the six major method groups in the FSH and LH schemes, respectively, over the 6 months to April 1986. Data for the previous 6 months are broadly similar. For anyone method. there is a remarkable similarity between the performance characteristics for FSH and LH, suggesting that assay design appears to be a more important predictor of performance than the specific nature of the gonadotrophin being measured.
METHOD GROUP BIAS
For both FSH and LH. the Arneriex (nonmagnetic), 'in-house' RIA. and Chelsea (solidphase) method groups generally agree well, giving median cumulative biases within ± J()'X, of the ALTM. The Arnerlex-M (magnetic) methods show 20-3()'Yo positive bias, most marked in the case of FSII. The Chelsea (liquid-phase) methods are more negatively biased than the corresponding solid-phase methods, with median cumulative biases to the ALTM of -J()% or greater. The high bias of the Becton Dickinson SimulTRAC kit in the FSH scheme should he interpreted with caution in view of the small number of laboratories using this kit (Table 4 ).
These differences in bias correspond. in the normal male range, to mean differences in concentration from the ALTM of about lUlL or less for the majority of the methods. an exception being the Arnerlcx-M FSH method which gives values on average 2 U/L higher. At levels greater than 10 U/L. the higher means for the Arnerlex-M methods are more marked. averaging 2 U/L for L11 and 4 U/L for FSH. These differences in method bias. even between similar methods from the same manufacturer, illustrate some of the difficulties in the design of reliable assays for gonadotrophins. The cause of these differences in bias is not clear. Differences in calibration seem unlikely to he an important factor. as recoveries of the appropriate IRP do not reveal major discrepancies between methods. It would appear that differences in susceptibility to non-specific One of the objectives of the UK EQAS and of this report is to shift laboratories away from the 'unacceptable' and 'adequate' performance categories into the 'good' performance group.
Whilst it is to be hoped that the new methods for FSH and LH (see Section 5) will result in an overall improvement in the level of performance, the widespread use of these techniques is still some years away, and positive suggestions are needed to try to improve existing assays.
There are no obvious distinguishing features between laboratories that have 'unacceptable' performance and those that have 'good' performance. In particular, no one method group has a significantly higher percentage of its users in the 'good' performance group. This implies
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that each of the four most widely used methods is capable of good performance and that no single method can be 'recommended' for FSH or LH. Good performance in an assay for FSH or LH is thus more a feature of the way a laboratory carries out the assay than of the method it uses.
GUIDELINES FOR GOOI) PERFORMANCF.
There is no foolproof system for ensuring good assay performance, nor are there many special features of FSH and LH as analytes which require special attention. In general, good performance is achieved by a combination of a sound method coupled with effective laboratory management, skilled operator and meticulous attention to detail. To illustrate this statement, 20 simple guidelines have been listed, attention to which should improve the chances of a laboratory achieving good performance: I operators to be trained fully in immunoassay techniques before performing routine assays; 2 operator continuity to be maintained wherever possible; 3 assays to be performed frequently (at least once a week); 4 specimens to be well mixed after thawing before sampling; 5 pipettes to be checked frequently for accuracy and precision; 6 consistent use of the same items of equipment (e.g. displacement pipettes) in all assays of a particular analyte; 7 kit protocols to be followed absolutely; X fresh batches of reagents or of kits to be introduced according to a planned timetable; I) all new reagents to be validated before use; 10 incubation and separation times and temperatures to be standardised; II centrifugation conditions (time, temperature and speed) to be standardised; 12 temperature of refrigerators and centrifuges to be monitored frequently; 13 laboratory area and y-counter to be monitored regularly for contamination; multihead counters to be checked regularly for balance between counting heads; 14 The between-assay counting time to be varied according to the age of the label so as to compensate for increasing counting errors. In practice this can be achieved by adjusting the assay counting time so that a predetermined number of counts accumulate in the zero-binding (B II ) tubes; adopted; 16 a strict code of quality control (including EQAS) to be used; 17 no results outside the working range of the curve to be reported, except as less than the sensitivity or greater than the upper limit of the working range; IX all assays to be checked by a person other than the operator before reporting; 19 all reports to be scrutinised by a biochemist/ pathologist experienced in interpreting gonadotrophin results; 20 regular meetings to discuss both internal quality control and UK EQAS performance, attended by all individuals involved with the gonadotrophin assays.
New techniques for the measurement of gonadotrophins
The next few years will sec a major change to the pattern of available assays for the measurement of FSII and LH. Two new principles <Ire likely to find widespread acceptance amongst analysts: immunornetric assays and nonisotopic labels. Monoclonal antibodies against defined epitopes on the FSH and L11 molecules arc now available. A plentiful supply of these pure antibodies of known specificity will lead to the development of various labelled antibody assays for gonadotrophins, foremost amongst which will be the two-site immunomctric or 'sandwich' assay. This assay design requires two antibodies against different epitopcs on the gonadotrophin molecule. one of which [Ab.) is coupled to a solid-phase. whilst the other (Ab~) is labelled. Both antibodies arc used in excess. and the amount of label appearing in the solidphase fraction will be directly proportional to the amount of antigen (Ag) present through the formation of the Ab,-Ag-Ab! sandwich.:" Immunometric assays of this design are more sensitive than conventional RIAs and cover <I much wider working range. They have the potential for improved specificity and should be relatively less susceptible to non-specific matrix effects. Finally, they should be much quicker to perform than an RIA. with same-day results easily achievable for gonadotrophin assays.:'" Immunoradiometric assays (IRMAs) for serum gonadotrophins (i.e. employing a radioactive label) have been described" and arc now available through NETRIA or commercially from Boots-Cclltech Diagnostics Ltd and RIA (UK) Ltd. Other commercial IRMAs for FSH and LH are likely to be available in the very near future.~7
The radioactive label imposes a limitation on the potential sensitivity of the two-site immunometric assay. since the specific radioactivity of the label restricts the amount of signal to a few hundred counts per minute at low levels of FSH and LH. By contrast. labels that generate light as an end point arc capable of producing > HlI> 'counts' per second, and this increased signal should reduce counting time and improve both precision and sensitivity. Recent experience with such optical labels has minimised the interference from non-specific factors, and they now provide a real alternative to radioactive labels, A commercial immunofluorometric assay (IFMA) for LH is now available, based on the principle of time-resolved fluorescence immunoassay .~~and it is probable that assays for both FSH and L11 will appear in the very near future using labels suitable for chemiluminescence immunoassav ,~X enhanced luminescence immunoassa/'( and enzyme arnplification.i" These developments are likely to transform the ability of the laboratory to provide rapid and precise gonadotrophin assays. However. a note of caution should be sounded. for it is possible that some antibody combinations may be vulnerable to minor structural differences between gonadotrophin in standard preparations and serum samples, thus introducing systematic bias. Such potency differences have been noted in an immunoradiometric assay for FSH (J Seth. personal communication) and in serum TSH. 5 \ 
